Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.

ABSTRACT:

Background

DNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNAs in the therapy is emerging. In this study, we explored whether miR-26a-5p could act as BRCAness and enhance chemotherapy sensitivity in TNBC.

Methods

Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-26a-5p in breast cancer tissues and cell lines. CCK-8 was used to measure drug sensitivity in concentration gradient and time gradient. Comet assay was used to detect DNA damage. Flow cytometry was performed to examine apoptosis. Moreover, we used western blot and immunofluorescence to detect biomark

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC10294332 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature